Tissue Regenix Group (LSE:TRX) Short-Term Debt: £0.42 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Tissue Regenix Group Short-Term Debt?

Tissue Regenix Group LSE:TRX Short-Term Debt is £0.42 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Tissue Regenix Group's Short-Term Debt for the quarter that ended in Jun. 2025 was £0.42 Mil.

Tissue Regenix Group's quarterly Short-Term Debt increased from Jun. 2024 (£0.43 Mil) to Dec. 2024 (£0.43 Mil) but then declined from Dec. 2024 (£0.43 Mil) to Jun. 2025 (£0.42 Mil).

Tissue Regenix Group's annual Short-Term Debt declined from Dec. 2022 (£0.82 Mil) to Dec. 2023 (£0.36 Mil) but then increased from Dec. 2023 (£0.36 Mil) to Dec. 2024 (£0.43 Mil).

Tissue Regenix Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Tissue Regenix Group Short-Term Debt Related Terms

Tissue Regenix Group Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Short-Term Debt Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.82 0.36 0.43

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.36 0.43 0.43 0.42
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of £0.42 Mil mean?
Tissue Regenix Group (LSE:TRX) has a Short-Term Debt of £0.42 Mil as of Jun. 2025.
Is Tissue Regenix Group's Short-Term Debt too high?
Tissue Regenix Group's current Short-Term Debt is £0.42 Mil.
How does Tissue Regenix Group's Short-Term Debt compare to VRTX and REGN?
Tissue Regenix Group's Short-Term Debt of £0.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Tissue Regenix Group's current Short-Term Debt is £0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current Short-Term Debt of £0.42 Mil. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current Short-Term Debt is £0.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current Short-Term Debt is £0.42 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.